Compare FTNT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTNT | VRTX |
|---|---|---|
| Founded | 2000 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4B | 128.8B |
| IPO Year | 2009 | 2006 |
| Metric | FTNT | VRTX |
|---|---|---|
| Price | $170.88 | $501.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 44 | 32 |
| Target Price | $167.91 | ★ $571.46 |
| AVG Volume (30 Days) | ★ 3.0M | 1.0M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.08 | ★ 836.54 |
| EPS | 1.54 | ★ 8.33 |
| Revenue | ★ $6,799,600,000.00 | $2,488,652,000.00 |
| Revenue This Year | $19.42 | $10.54 |
| Revenue Next Year | $11.23 | $9.74 |
| P/E Ratio | $109.68 | ★ $59.93 |
| Revenue Growth | 14.17 | ★ 46.20 |
| 52 Week Low | $73.55 | $403.16 |
| 52 Week High | $197.13 | $560.25 |
| Indicator | FTNT | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 44.56 |
| Support Level | $146.01 | $498.58 |
| Resistance Level | $172.11 | $506.93 |
| Average True Range (ATR) | 5.60 | 11.23 |
| MACD | -2.41 | -0.60 |
| Stochastic Oscillator | 14.52 | 36.97 |
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.